Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts

Agenus Inc. (NASDAQ:AGEN) has earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $10.00.

Separately, HC Wainwright reissued a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th.

Agenus Stock Performance

NASDAQ AGEN opened at $2.83 on Monday. The firm has a market capitalization of $66.39 million, a price-to-earnings ratio of -0.25 and a beta of 1.24. Agenus has a one year low of $2.50 and a one year high of $19.69. The company’s 50 day moving average price is $3.67 and its 200 day moving average price is $7.16.

Hedge Funds Weigh In On Agenus

Several hedge funds and other institutional investors have recently bought and sold shares of AGEN. Point72 DIFC Ltd purchased a new stake in shares of Agenus during the second quarter valued at approximately $51,000. EP Wealth Advisors LLC acquired a new stake in Agenus during the 3rd quarter valued at $55,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Agenus during the 2nd quarter worth $106,000. HighTower Advisors LLC lifted its holdings in Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after buying an additional 7,530 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in Agenus by 52.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after buying an additional 9,422 shares in the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.